Antares Prof Dividend Builder is an Managed Funds investment product that is benchmarked against ASX Index 200 Index and sits inside the Domestic Equity - Large Value Index. Think of a benchmark as a standard where investment performance can be measured. Typically, market indices like the ASX200 and market-segment stock indexes are used for this purpose. The Antares Prof Dividend Builder has Assets Under Management of 130.46 M with a management fee of 0.6%, a performance fee of 0.00% and a buy/sell spread fee of 0.31%.
Australian shares disappointed in August with a mild decline given concerns over China’s prospects as well as the Australian consumer. The Utilities and Consumer Staples sectors led the market declines given concerns about the consumer’s ability to absorb higher electricity & gas prices as well as rising mortgage interest rates and rents. Information Technology declined in line with a more cautious view after their recent strong gains. Despite a rebound in the iron ore price to above US$110 per ton, the Resources sector posted a -1.8% negative return with concerns over China’s prospects. There were some positives with surprisingly strong gains for Consumer Discretionary and Real Estate on hopes that the Reserve Bank has ceased raising interest rates.
August is also reporting season for most Australian companies and while results were largely in line with expectations, the prospect of rising costs and a slowing economy saw reasonably soft guidance for the FY24 year which flowed through to earnings downgrades.
The annual distribution return to 31 August 2023 for the Antares Dividend Builder Fund was 5.4%. The fund delivered a total return of -1.6% (net of fees) for the month of August which compared to a return of -0.7% for the S&P/ASX200 Total Return Index. Dividends were received from Metcash, Region and Transurban during the month.
Contributing to the Fund’s performance was an overweight Medibank Private (MPL) holding and decisions not to own Resmed (RES) or Wisetech (WTC). MPL delivered a strong profit result for FY23 and a higher dividend. As well as a boost to investment income, the company reported an increase in net policy holders which it attributed to its customer focus. RES’ 4Q result was below market expectations, driven by lower margins and higher costs. There is also some concern that the increased use of Ozempic for weight loss could reduce the prospect of sleep apnoea and subsequent demand for RES’ machines.
Product Snapshot
Performance Review
Product Overview
Peer Comparison
Product Details